Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

ARIAD Pharmaceuticals Inc

+ Add to Watchlist

ARIA:US

8.5600 USD 0.1700 2.03%

As of 20:10:00 ET on 03/30/2015.

Snapshot for ARIAD Pharmaceuticals Inc (ARIA)

Open: 8.3900 Day's Range: 8.3900 - 8.6850 Volume: 6,523,040
Previous Close: 8.3900 52wk Range: 4.9000 - 9.1900 1-Yr Rtn: +7.27%

Stock Chart for ARIA

No chart data available.
  • ARIA:US 8.5600
  • 1D
  • 1M
  • 1Y
8.3900
Interactive ARIA Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ARIA

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.8700
Est. EPS (USD) (12/2015) -1.0120
Est. PEG Ratio -
Market Cap (M USD) 1,605.27
Shares Outstanding (M) 187.53
30 Day Average Volume 7,145,855
Price/Book (mrq) 19.8418
Price/Sale (ttm) 15.1887
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/07/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ARIA

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for ARIA

ARIAD Pharmaceuticals, Inc. is a global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. The Company's approach to structure-based drug design has led to several molecularly targeted medicines for drug-resistant or difficult-to-treat cancers.

Harvey J BergerChairman/President/CEOTimothy P ClacksonChief Scientific Ofcr/Pres:R&D
Edward M FitzgeraldExec VP/CFO/TreasurerMartin J Duvall "Marty"Exec VP/Chief Commercial Ofcr
More Company Profile & Key Executives for ARIA

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil